Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with type 2 diabetes within the last 24 months, based on a doctor's assessment
- People aged 30 to 80 years old
- People whose HbA1c blood sugar level (a measure of average blood sugar over time) is between 6.5% and 11%, based on a test result from the last 6 months
- People who have access to a smartphone throughout the study period
- People who have had a diabetes-related medical appointment within the 12 months before screening
- People taking medications that affect weight (such as GLP-1 or GIP medications) must have been on a stable dose for approximately four weeks
Who may not be able to join:
- People who have taken medications known to make weight loss harder in the last 3 months, as determined by the study doctors
- People taking certain psychiatric medications that could raise blood sugar levels, as determined by the study doctors
- People with conditions that would make study participation difficult, such as severe mental health conditions (for example, bipolar disorder or severe depression) or active substance abuse
- People with conditions that would prevent them from safely increasing physical activity, such as severe nerve damage, heart disease, severe lung disease, severe joint disease, or a history of stroke
- People with conditions that would prevent them from following the study's self-directed program, including being unable to read English, active substance abuse, or severe depression
- People with conditions that restrict their diet, such as severe stomach-emptying problems, ulcers, or significant food allergies
- People with severe vision impairment that, in the lead researcher's opinion, would prevent them from reading study materials or using the provided devices
- People currently receiving cancer treatment that, in the lead researcher's opinion, would affect safe participation
- People with significant kidney disease (for example, an eGFR below 45, which indicates reduced kidney function) (confirm with trial site)
- People who are currently pregnant or planning to become pregnant within the next 14 months
- People who are currently breastfeeding
- People with any other condition that, in the lead researcher's opinion, could interfere with safely completing the study
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Chiara Fabris, PhD, University of Virginia Center for Diabetes Technology
Phone: 434-422-2653
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Hemoglobin A1c at 4.5-months of follow-up; Change in Hemoglobin A1c at the 13.5-months of follow-up; Change in Metformin at 4.5-months of follow-up; Change in Metformin at 13.5-months of follow-up
Can't join this trial?
Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.